Skip to content

The Mechanism and Clinical Study of Heat-sensitive Moxibustion in Improving Immune Function and Myelosuppression in NSCLC Chemotherapy

The Mechanism and Clinical Study of Heat-sensitive Moxibustion in Improving Immune Function and Myelosuppression in NSCLC Chemotherapy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001099
Enrollment
Unknown
Registered
2025-06-03
Start date
2025-03-31
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

experiment group:Chemotherapy+heat-sensitive moxibustion
control group:Chemotherapy

Sponsors

Guangdong Provincial Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) All cases were based on the above-mentioned diagnostic criteria of traditional Chinese and Western medicine; (2) Patients aged between 18 and 75 years old with normal blood images liver and kidney function and electrocardiogram before chemotherapy and no symptoms of infection or fever; (3) Those who meet the indications for chemotherapy and plan to undergo chemotherapy treatment with a KPS score of = 60 points no damage to important organs and the condition will not deteriorate rapidly in the short term and the expected survival time is = 3 months; (4) Patients with high degree of cooperation clear consciousness and no abnormality in language expression ability should voluntarily participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Previous chemotherapy treatment. (2) Patients with severe liver and kidney dysfunction and severe cardiovascular disease. (3) Patients with incomplete clinical data. (4) Patients with mental illness and cognitive dysfunction. (5) Patients with respiratory failure. (6) Those who are receiving targeted therapy biological therapy and other treatments.

Design outcomes

Primary

MeasureTime frame
Immune function level;

Secondary

MeasureTime frame
QLQ-C30;Karnofsky Performance Status;Evaluation of toxicity and adverse effects of chemotherapy;TCM syndrome scale;

Countries

China

Contacts

Public ContactZhiwei DONG

Affiliated Guangdong Hospital of Integrated Chinese and Western Medicine of Guangzhou University of Chinese Medicine

20232120290@stu.gzucm.edu.cn0757-86288564

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026